Poliomyelitis disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

POLIO MCID: PLM031 MIFTS: 63	Poliomyelitis (POLIO) Categories: Infectious diseases, Muscle diseases, Neuronal diseases, Oral diseases, Rare diseases	Data Licensing For inquiries, contact: [email protected]
Genes Tissues Related diseases Publications Symptoms & Phenotypes Drugs Expand all tables

Sources

Aliases & Classifications for Poliomyelitis

MalaCards integrated aliases for Poliomyelitis:

Name: Poliomyelitis ¹¹ ¹⁹ ⁵⁸ ⁷⁵ ⁴³ ¹⁴ ¹⁶ ⁷¹

Polio ¹⁹ ⁵³ ⁷⁵

Infantile Paralysis ¹⁹ ⁷¹

Characteristics:

Prevelance:

<1/1000000 (Europe) ⁵⁸

Age Of Onset:

Childhood ⁵⁸

Classifications:

MalaCards categories:
Global: Rare diseases Infectious diseases
Anatomical: Neuronal diseases Muscle diseases Oral diseases

See all MalaCards categories (disease lists)

ICD10: ³¹ ³²

Certain infectious and parasitic diseases

Viral infections of the central nervous system

Acute poliomyelitis

Acute nonparalytic poliomyelitis

Acute paralytic poliomyelitis, other and unspecified

Acute paralytic poliomyelitis, vaccine-associated

Acute paralytic poliomyelitis, wild virus, imported

Acute paralytic poliomyelitis, wild virus, indigenous

Acute poliomyelitis, unspecified

Orphanet: ⁵⁸

Rare neurological diseases

Sources

Summaries for Poliomyelitis

GARD: ¹⁹ Poliomyelitis is a viral disease that can affect nerves and can lead to partial or full paralysis. It is caused by infection with the poliovirus which can be spread by direct person-to-person contact, by contact with infected mucus or phlegm from the nose or mouth, or by contact with infected feces. There are three basic patterns of polio infection: subclinical infections, nonparalytic, and paralytic. Symptoms vary based on the pattern of infection and can range from asymptomatic with subclinical Poliomyelitis to partial or full paralysis. Since the development of the polio vaccine, the incidence of the disease has been greatly reduced.

MalaCards based summary: Poliomyelitis, also known as polio, is related to nonparalytic poliomyelitis and paralytic poliomyelitis. An important gene associated with Poliomyelitis is PVR (PVR Cell Adhesion Molecule), and among its related pathways/superpathways are Disease and TGF-Beta Pathway. The drugs Edetate calcium disodium anhydrous and Iron have been mentioned in the context of this disorder. Affiliated tissues include spinal cord, skeletal muscle and bone marrow, and related phenotypes are vomiting and fatigue

Disease Ontology: ¹¹ A viral infectious disease that results in destruction located in motor neurons, has material basis in Human poliovirus 1, has material basis in Human poliovirus 2, or has material basis in Human poliovirus 3, which are transmitted by ingestion of food or water contaminated with feces, or transmitted by direct contact with the oral secretions. The infection has symptom fever, has symptom sore throat, has symptom headache, has symptom vomiting, has symptom fatigue, has symptom neck stiffness, has symptom muscle spasms, and has symptom acute flaccid paralysis.

Orphanet: ⁵⁸ Poliomyelitis is a viral infection caused by any of three serotypes of human poliovirus, which is part of the family of enteroviruses.

Wikipedia: ⁷⁵ Poliomyelitis, commonly shortened to polio, is an infectious disease caused by the poliovirus.... more...

Sources

Related Diseases for Poliomyelitis

Diseases related to Poliomyelitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 954)

#	Related Disease	Score	Top Affiliating Genes
1	nonparalytic poliomyelitis	32.8	PI4KB ACBD3
2	paralytic poliomyelitis	32.5	TLR3 RASA3 PVR CD8A CD4 BTK
3	smallpox	31.0	TNF IFNG ICAM1
4	west nile encephalitis	30.9	TNF TLR3 RIGI IL10 IFNG IFNB1
5	facial paralysis	30.8	TNF CD8A CD4
6	encephalitis	30.8	TNF TLR3 RIGI IL10 IFNB1
7	aseptic meningitis	30.8	TNF IL10 CD8A CD4
8	myelitis	30.8	TNF IL10 IFNB1
9	meningitis	30.8	TNF IL10 IFNG ICAM1 HLA-B FCGR2A
10	neuritis	30.7	TNF IL10 IFNG
11	bell's palsy	30.7	TNF TLR3 CD8A CD4
12	mumps	30.6	TNF TLR3 IL10 IFNG IFNB1
13	tick-borne encephalitis	30.5	TLR3 CD8A CD4
14	human immunodeficiency virus type 1	30.5	TLR3 IL10 IFNG HLA-B CD4
15	respiratory failure	30.4	TNF TLR3 IL10 IFNG IFNB1 ICAM1
16	meningoencephalitis	30.4	TNF IL10 CD8A CD4
17	myocarditis	30.4	TNF TLR3 IL10 IFNG ICAM1 CD4
18	acquired immunodeficiency syndrome	30.4	TNF IL10 IFNG ICAM1 HLA-B FCGR3A
19	vaccinia	30.4	TNF IFNB1 ICAM1 HLA-B
20	acute asthma	30.4	TNF IL10 ICAM1 CD4
21	herpes simplex	30.3	TLR3 RIGI IFNB1 CD8A
22	graft-versus-host disease	30.3	TNF IL10 IFNG
23	syphilis	30.3	TNF CD8A CD4
24	osteomyelitis	30.3	TNF IL10 IFNG
25	acute disseminated encephalomyelitis	30.3	IFNB1 CD8A CD4
26	chronic fatigue syndrome	30.2	TNF IL10 IFNG CD8A CD4
27	optic neuritis	30.2	TNF IL10 HLA-B
28	acute flaccid myelitis	30.2	PVR PI4KB ACBD3
29	hepatitis b	30.2	TNF TLR3 RIGI IFNG IFNB1
30	myasthenia gravis	30.2	TNF IL10 IFNG HLA-B FCGR2A
31	rubella	30.2	TNF TLR3 RIGI IL10 IFNG IFNB1
32	japanese encephalitis	30.1	TLR3 RIGI IFNB1 CD8A CD4
33	ebola hemorrhagic fever	30.1	TNF TLR3 RIGI IL10 IFNB1 CD8A
34	viral encephalitis	30.1	TNF TLR3 RIGI IL10 IFNB1 CD8A
35	sleep apnea	30.1	TNF IL10 ICAM1
36	pulmonary edema	30.0	TNF IL10 ICAM1
37	common variable immunodeficiency	30.0	TNF IL10 IFNG HLA-B BTK
38	toxoplasmosis	30.0	TNF IL10 IFNG
39	brucellosis	30.0	TNF IL10 IFNG HLA-B
40	spondylitis	30.0	TNF IL10 IFNG HLA-B
41	pfeiffer syndrome	30.0	TNF IL10 CD8A CD4
42	viral infectious disease	30.0	TNF TLR3 RIGI IL10 IFNG IFNB1
43	penicillin allergy	30.0	IL10 IFNG HLA-B
44	immunoglobulin alpha deficiency	30.0	IL10 CD8A CD4
45	thrombocytopenic purpura, autoimmune	30.0	FCGR2A CD8A CD4
46	septic arthritis	29.9	TNF IL10 CD4
47	hepatitis a	29.9	TNF TLR3 IL10 IFNG CD4
48	epidemic typhus	29.9	IL10 CD8A CD4
49	actinomycosis	29.9	TNF IL10 CD4
50	spinal cord disease	29.9	TNF IL10 IFNB1 CD8A CD4

Graphical network of the top 20 diseases related to Poliomyelitis:

Sources

Symptoms & Phenotypes for Poliomyelitis

Human phenotypes related to Poliomyelitis:

⁵⁸ ³⁰ (show top 50) (show all 54)

#	Description	HPO Frequency	Orphanet Frequency	HPO Source Accession
1	vomiting ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0002013
2	fatigue ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0012378
3	fever ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0001945
4	skeletal muscle atrophy ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0003202
5	anorexia ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0002039
6	arthralgia ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0002829
7	myalgia ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0003326
8	areflexia ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0001284
9	meningitis ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0001287
10	headache ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0002315
11	hypoplasia of the musculature ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0009004
12	muscle flaccidity ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0010547
13	functional motor deficit ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0004302
14	brisk reflexes ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0001348
15	pharyngitis ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0025439
16	paralysis ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0003470
17	nausea ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0002018
18	stiff neck ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0025258
19	exercise intolerance ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0003546
20	lower limb muscle weakness ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0007340
21	myelitis ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0012486
22	abnormal motor nerve conduction velocity ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0040131
23	low self esteem ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0031469
24	dysphonia ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0001618
25	dysphagia ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0002015
26	cranial nerve paralysis ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0006824
27	immunodeficiency ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0002721
28	bulbar signs ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0002483
29	paresthesia ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0003401
30	fasciculations ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0002380
31	respiratory failure ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0002878
32	paraparesis ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0002385
33	upper limb muscle weakness ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0003484
34	inability to walk ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0002540
35	bulbar palsy ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0001283
36	fatigable weakness of respiratory muscles ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0030196
37	hyperkinetic movements ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0002487
38	respiratory failure requiring assisted ventilation ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0004887
39	absent tonsils ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0030813
40	diminished movement ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0002374
41	impairment of activities of daily living ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0031058
42	paralytic ileus ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0002590
43	hypotension ⁵⁸ ³⁰	Very rare (1%)	Very rare (<4-1%)	HP:0002615
44	hypertension ⁵⁸ ³⁰	Very rare (1%)	Very rare (<4-1%)	HP:0000822
45	irritability ⁵⁸ ³⁰	Very rare (1%)	Very rare (<4-1%)	HP:0000737
46	coma ⁵⁸ ³⁰	Very rare (1%)	Very rare (<4-1%)	HP:0001259
47	confusion ⁵⁸ ³⁰	Very rare (1%)	Very rare (<4-1%)	HP:0001289
48	agitation ⁵⁸ ³⁰	Very rare (1%)	Very rare (<4-1%)	HP:0000713
49	hypovolemic shock ⁵⁸ ³⁰	Very rare (1%)	Very rare (<4-1%)	HP:0031274
50	infectious encephalitis ³⁰	Very rare (1%)		HP:0002383

GenomeRNAi Phenotypes related to Poliomyelitis according to GeneCards Suite gene sharing:

²⁵ (show all 20)

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	no effect	GR00402-S-1	10.13	ACBD3 BTK CD4 CD8A DLG1 EIF4G1
2	no effect	GR00402-S-2	10.13	ACBD3 BTK CD4 DLG1 FCGR2A FCGR3B
3	Increased shRNA abundance (Z-score > 2)	GR00366-A-104	9.96	PVR
4	Increased shRNA abundance (Z-score > 2)	GR00366-A-118	9.96	HLA-B
5	Increased shRNA abundance (Z-score > 2)	GR00366-A-123	9.96	PVR
6	Increased shRNA abundance (Z-score > 2)	GR00366-A-14	9.96	CD4
7	Increased shRNA abundance (Z-score > 2)	GR00366-A-147	9.96	CD4
8	Increased shRNA abundance (Z-score > 2)	GR00366-A-160	9.96	CD4
9	Increased shRNA abundance (Z-score > 2)	GR00366-A-162	9.96	PVR
10	Increased shRNA abundance (Z-score > 2)	GR00366-A-180	9.96	PVR
11	Increased shRNA abundance (Z-score > 2)	GR00366-A-19	9.96	CD4 EIF4G1 PVR
12	Increased shRNA abundance (Z-score > 2)	GR00366-A-32	9.96	CD4
13	Increased shRNA abundance (Z-score > 2)	GR00366-A-46	9.96	PVR
14	Increased shRNA abundance (Z-score > 2)	GR00366-A-6	9.96	PVR
15	Increased shRNA abundance (Z-score > 2)	GR00366-A-60	9.96	EIF4G1
16	Increased shRNA abundance (Z-score > 2)	GR00366-A-63	9.96	PVR
17	Increased shRNA abundance (Z-score > 2)	GR00366-A-65	9.96	PVR
18	Increased shRNA abundance (Z-score > 2)	GR00366-A-68	9.96	EIF4G1
19	Increased shRNA abundance (Z-score > 2)	GR00366-A-74	9.96	HLA-B
20	Increased shRNA abundance (Z-score > 2)	GR00366-A-94	9.96	EIF4G1

MGI Mouse Phenotypes related to Poliomyelitis:

⁴⁵

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	homeostasis/metabolism	MP:0005376	10.27	ACBD3 BTK CD4 DLG1 FCGR2A FCGR3A
2	nervous system	MP:0003631	10.22	CD4 CD8A DLG1 EIF4G1 FCGR2A HLA-B
3	no phenotypic analysis	MP:0003012	10.13	CD4 DLG1 EIF4G1 FCGR3A FCGR3B HLA-B
4	neoplasm	MP:0002006	10.11	BTK ICAM1 IFNB1 IFNG IL10 PVR
5	immune system	MP:0005387	10.09	BTK CD4 CD8A DLG1 FCGR2A FCGR3A
6	endocrine/exocrine gland	MP:0005379	10.02	CD4 CD8A DLG1 FCGR2A HLA-B ICAM1
7	digestive/alimentary	MP:0005381	9.96	BTK CD4 DLG1 FCGR2A HLA-B ICAM1
8	hematopoietic system	MP:0005397	9.91	ACBD3 BTK CD4 CD8A DLG1 FCGR2A
9	mortality/aging	MP:0010768	9.47	ACBD3 BTK CD4 CD8A DLG1 FCGR2A

Sources

Drugs & Therapeutics for Poliomyelitis

Drugs for Poliomyelitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 64)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Edetate calcium disodium anhydrous

Approved, Vet_approved

Phase 4

62-33-9, 60-00-4

6049

Iron

Approved

Phase 4

7439-89-6

29936

Pentetic acid

Approved

Phase 4

67-43-6

Zinc cation

Approved, Experimental, Investigational

Phase 4

7440-66-6, 23713-49-7

32051

Zinc sulfate

Approved, Investigational

Phase 4

7733-02-0

Calcium carbonate

Approved, Investigational

Phase 4

471-34-1

Inulin

Approved, Investigational, Nutraceutical

Phase 4

9005-80-5

24763

Antibodies, Blocking

Phase 4

PENTA

Phase 4

Fibrinolytic Agents

Phase 4

Anticoagulants

Phase 4

Iron Chelating Agents

Phase 4

Antidotes

Phase 4

Chelating Agents

Phase 4

Zinc Supplement

Phase 4

Acidophilus

Phase 4

Trace Elements

Phase 4

Micronutrients

Phase 4

Deferiprone

Approved

Phase 3

30652-11-0

2972

Framycetin

Approved, Experimental, Vet_approved

Phase 3

1404-04-2, 119-04-0, 3947-65-7

413349 8378

Polymyxin B

Approved, Vet_approved

Phase 3

1405-20-5, 1404-26-8

4868

Ethanol

Approved

Phase 3

64-17-5

702

Streptomycin

Approved, Vet_approved

Phase 3

57-92-1

19649

Modafinil

Approved, Investigational

Phase 3

68693-11-8

4236

Glycine

Approved, Nutraceutical, Vet_approved

Phase 3

56-40-6

750

Heptavalent Pneumococcal Conjugate Vaccine

Phase 3

Somatomedin B

Phase 3

Hemagglutinins

Phase 3

Taxane

Phase 3

108169

Immunoglobulins

Phase 2, Phase 3

Antibodies

Phase 2, Phase 3

Immunoglobulins, Intravenous

Phase 2, Phase 3

gamma-Globulins

Phase 2, Phase 3

Rho(D) Immune Globulin

Phase 2, Phase 3

Polymyxins

Phase 3

Vitamins

Phase 3

Anti-Bacterial Agents

Phase 3

Antibiotics, Antitubercular

Phase 3

Vaccines

Phase 3

Protective Agents

Phase 3

Neuroprotective Agents

Phase 3

Central Nervous System Stimulants

Phase 3

Aluminum hydroxide

Approved, Investigational

Phase 1, Phase 2

21645-51-2

Racepinephrine

Approved, Vet_approved

Phase 2

51-43-4, 329-65-7

838 5816

Phenol

Approved, Experimental

Phase 2

108-95-2

996

Magnesium sulfate

Approved, Investigational, Vet_approved

Phase 2

7487-88-9

Epinephryl borate

Phase 2

Calcium, Dietary

Phase 2

Calcium

Nutraceutical

Phase 2

7440-70-2

271

Arginine

Approved, Investigational, Nutraceutical

Phase 1

74-79-3

6322

Interventional clinical trials:

(show top 50) (show all 255)

#	Name	Status	NCT ID	Phase	Drugs
1	Comparison of Immunity Following Inactivated Poliovirus Vaccine Versus Fractional Dose Inactivated Poliovirus Vaccine: a Community Based Randomized Controlled Trial in Pakistan	Unknown status	NCT03286803	Phase 4
2	A Phase 4, Randomized, Open-Label Study to Assess Humoral and Intestinal Polio Immunity Following a Three-Dose Trivalent Inactivated Polio Vaccine Schedule Relative to Two Sequential Schedules of IPV/Bivalent Oral Polio Vaccines	Unknown status	NCT01841671	Phase 4
3	A Randomized, Controlled, Multicenter Phase 4 Clinic Trial to Evaluate the Immunogenicity and Safety of Combined Immunization of Sabin-strain Inactivated Polio Vaccine (sIPV), Diphtheria, Tetanus, Pertussis Vaccine (DTaP) and Measles, Moms and Rubella Vaccine (MMR)	Unknown status	NCT04638985	Phase 4
4	A Randomized, Controlled, Multicenter Phase 4 Clinic Trial to Evaluate the Safety and Immunogenicity of Combined Immunization of Sabin-strain Inactivated Polio Vaccine (sIPV), Diphtheria, Tetanus, Pertussis (DTaP) Vaccine and Live Attenuated Hepatitis A Vaccine (HepA)	Unknown status	NCT04636827	Phase 4
5	Immunogenicity and Safety of Different Sequential Schedules of Inactivated Poliomyelitis Vaccine (IMOVAX Polio®) Followed by Oral Poliomyelitis Vaccine in Healthy Infants in China Versus Oral Poliomyelitis Vaccine Alone.	Completed	NCT01475539	Phase 4
6	An Open, Multicentric, Post-marketing Surveillance Study to Assess the Safety and Reactogenicity of GlaxoSmithKline Biologicals' DTPa-IPV/Hib Vaccine Administered at 3, 4, 5 and 18 Months of Age, in Healthy Infants.	Completed	NCT00325156	Phase 4
7	Immunogenicity and Safety Study of GSK Biologicals' Combined Diphtheria-tetanus-acellular Pertussis-hepatitis B-inactivated Polio-virus and Haemophilus Influenzae Type b Vaccine (Infanrix Hexa™) (217744) in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-delivery	Completed	NCT02422264	Phase 4	Prevnar13
8	Antibody Persistence in Children Previously Vaccinated With Three Doses of Infanrix Hexa™ or Infanrix-IPV/Hib™	Completed	NCT01358825	Phase 4
9	Immunogenicity and Safety Study of a Booster Dose of GSK Biologicals' Infanrix Hexa™ (217744) in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-delivery	Completed	NCT02853929	Phase 4
10	Phase IV Safety Monitoring Study of Inactivated Poliomyelitis Vaccine Made From Sabin Strain	Completed	NCT04220515	Phase 4
11	Consistency Study for Three Commercial Lots of Inactivated Poliomyelitis Vaccine Made From Sabin Strain	Completed	NCT04224519	Phase 4
12	Regulatory Post-Marketing Surveillance (PMS) Study for TETRAXIM™(Combined Vaccine of Adsorbed Diphtheria, Tetanus, Acellular Pertussis and Enhanced Inactivated Poliomyelitis)	Completed	NCT01437423	Phase 4
13	Cross-sectional Study to Assess Persistence of Immunity Conferred by a Single IPV Dose Administered in the Expanded Program on Immunization(EPI) Routine Immunization Schedule	Completed	NCT03723837	Phase 4
14	A Phase 4, Randomized Trial to Assess the Safety and Immunogenicity of Inactivated Poliovirus Vaccine When Given Concomitantly With Measles and Rubella Combined Vaccine and Yellow Fever Vaccine at Nine Months and When Administered Via Different Vaccination Routes	Completed	NCT01847872	Phase 4	IPV IM Needle;IPV ID Needle;IPV IM Device;IPV ID Device
15	Evaluation of GSK Biological's dTpa-IPV Booster Vaccine in Children and Adolescents, 5 Years After Previous dTpa-IPV Boosting.	Completed	NCT00635128	Phase 4
16	Assessing Immunogenicity of Type 2 Monovalent Oral Poliovirus Vaccine Administered at One, Two or Four Week Intervals and When Coadministered With Inactivated Poliovirus Vaccine in an Urban Area in Bangladesh	Completed	NCT02643368	Phase 4
17	A Phase 4 Study to Evaluate the Safety and Immunogenicity of Trivalent Oral Polio Vaccine in Healthy Polio Vaccinated Children 1 to 5 Years of Age and in Healthy Unvaccinated Infants at 6 Weeks of Age in the Dominican Republic	Completed	NCT02580201	Phase 4
18	A Phase 4, Randomized Study to Evaluate the Safety and the Humoral and Intestinal Immunogenicity of One or Two Additional Doses of Licensed Inactivated Polio Vaccines (IPVs) in Latin American Infants Previously Vaccinated With Bivalent Oral Polio Vaccines (bOPVs)	Completed	NCT01831050	Phase 4
19	A Phase 4 Study to Evaluate the Safety and Immunogenicity of Monovalent Oral Polio Vaccine Type 2 in Healthy IPV-vaccinated Children Aged 1 to 5 Years in Lithuania	Completed	NCT02582255	Phase 4
20	Intestinal and Humoral Immunity of Monovalent Oral Poliovirus Vaccine Type 1 When Administered With and Without Fractional Inactivated Poliovirus Vaccine	Completed	NCT03722004	Phase 4
21	Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' Infanrix Hexa Vaccine in Healthy Infants	Completed	NCT00753649	Phase 4
22	Immunogenicity and Safety of IMOVAX POLIO® Subcutaneous as a Booster Given in Pre-school Age Children in Japan	Completed	NCT02005536	Phase 4
23	Assessing the Intestinal and Humoral Immunity of Sequential Schedules of Inactivated Poliovirus Vaccine and Bivalent Oral Poliovirus Vaccine for Routine Childhood Immunization in Bangladesh	Completed	NCT02412514	Phase 4
24	Immunogenicity and Reactogenicity Study of a New Formulation of GSK Biologicals' DTPa-HBV-IPV/Hib Vaccine Administered as a Booster Dose to 18-23 Months Old Children	Completed	NCT00611559	Phase 4
25	A Phase IV (Not Interventional), Open-label, Multicentre Study to Evaluate the Reactogenicity and Safety of Co-administration of GlaxoSmithKline Biologicals' DTPa (Infanrix) and IPV (Poliorix) Vaccines Administered as Three-dose Primary Immunisation Course at 3, 4.5 and 6 Months of Age in Healthy Children in Russian Federation	Completed	NCT01094171	Phase 4
26	Duration of Priming and Antibody Decay With Full-dose Inactivated Poliovirus Vaccine (IPV) Administered With or Without Bivalent Oral Poliovirus Vaccine (bOPV)	Completed	NCT03202719	Phase 4
27	Sero-conversion Study for a Two-dose Schedule of Sabin Strain Inactivated Poliovirus Vaccine in China	Completed	NCT03546634	Phase 4
28	Immunogenicity and Safety of the Sanofi Pasteur's DTacP-IPV Combined Vaccine (TETRAXIM™) Given as a Booster Dose at 4 to 6 Years of Life in Children Previously Vaccinated With PENTAXIM™ in the Study E2I34	Completed	NCT01031303	Phase 4
29	Evaluation of the Persistence of the Immunity in 4-year-old Children Previously Immunised With an Adjuvanted Reduced Dose Inactivated Polio Vaccine, IPV-Al AJV (Picovax®) by Measuring the Response to an Additional Dose of IPV-Al AJV	Completed	NCT04448132	Phase 4
30	Reactogenicity of Acellular Pertussis Vaccine Booster in Adolescents Who Have Received 5 Prior Doses of BIKEN Acellular Pertussis Vaccine in Combination With Diphtheria and Tetanus Toxoids (TRIPEDIA®) or Who Have Received Primary Vaccination With 3 Doses of Whole-Cell Pertussis Vaccine, Plus at Least 1 Pertussis Booster Vaccination	Completed	NCT00304265	Phase 4
31	Immunogenicity and Safety of Sanofi Pasteur Pentaxim Combined Vaccine in Infants in Thailand	Completed	NCT00255021	Phase 4
32	A Study of Immunogenicity and Seroconversion With Sabin Inactivated Polio Vaccine Schedules in China.	Completed	NCT03597919	Phase 4
33	Safety Study of IMOVAX Polio™ in Selected Cities in China, an Observational Post Marketing Study	Completed	NCT01244464	Phase 4
34	Large Scale Safety Study of IMOVAX Polio in Selected Cities in China, an Observational Post Marketing Study	Completed	NCT01278433	Phase 4
35	Antibody Persistence in 11 to 13-year-old Children Previously Vaccinated at 6 Years Old With Either REVAXIS or DT Polio, and Immune Response to a Booster Dose of TETRAVAC-ACELLULAIRE	Completed	NCT01546909	Phase 4
36	Evaluation of GSK Biologicals' Boostrix™ Polio in Healthy Adults, 10 Years After a Booster Vaccination	Completed	NCT01323959	Phase 4
37	Study to Assess and Compare the Immunogenicity and Reactogenicity of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (INFANRIX™ HEXA) and Aventis Pasteur MSD's DTPa-HBV-IPV-Hib Vaccine (HEXAVAC™) Given at 3, 5 and 11-12 Months of Age	Completed	NCT01457547	Phase 4
38	Polio End-game Strategies - Poliovirus Type 2 Challenge Study	Completed	NCT02189811	Phase 4
39	Immunogenicity of a Booster Dose of Fractional Inactivated Poliovirus Vaccine (fIPV) Delivered Intradermally Concomitantly With Rotavirus Vaccines	Completed	NCT02847026	Phase 4
40	Immunogenicity of Combined Bivalent OPV and IPV Vaccines at 9 - 12 Months of Age Compared to bOPV Alone in Malnourished and Non-Malnourished Pakistani Infants.	Completed	NCT01695798	Phase 4
41	Immunogenicity and Safety of the Booster Dose of Polio Vaccine Immunization Using Sabin IPV or bOPV at Children Aged 4 Years With Different Three Sequential Schedules History by Sabin IPV or bOPV in China	Completed	NCT04576910	Phase 4
42	Open Clinical Study to Assess the Immune Response and Safety of a Booster Dose (5th Dose) of a Combination Vaccine Against Diphteria-Tetanus-Pertussis-Polio Given to Healthy Adolescents 15-16 Years of Age.	Completed	NCT00514059	Phase 4	Boostrix polio
43	Supplementation With Zinc and/or Probiotics to Enhance the Immune Response of Oral Rotavirus and Polio Vaccines in Indian Infants	Completed	NCT01616693	Phase 4
44	a Randomized, Controlled Clinical Trial of Immunogenicity and Safety of Sabin-based Inactivated Polio Vaccine Replacing Salk-based Inactivated Polio Vaccine	Completed	NCT04051736	Phase 4
45	Safety and Immunogenicity of DAPTACEL® (CP10/5/5/3DT Aventis Pasteur 5-component Pertussis Vaccine in Combination With Tetanus and Diphtheria Toxoids Adsorbed) Administered as a 5th Dose in 4 to 6-Year-Old Children Previously Immunized With PENTACEL™ (HCP20/20/5/3DT-mIPV//PRP-T)	Completed	NCT00802867	Phase 4
46	Assessment of the Immunogenicity and Safety of PENTAXIM™ in Philippines	Completed	NCT00254917	Phase 4
47	Immunogenicity and Safety Evaluation of Different Sequential Immunization Strategies by Sabin IPV and bOPV in Chinese Infants	Completed	NCT03147560	Phase 4
48	Safety of the DTacP-IPV//PRP~T Combined Vaccine (PENTAXIM®) Given as a Three-Dose Primary Vaccination at 2, 3, and 4 Months of Age in Infants in China	Completed	NCT01491087	Phase 4
49	A Phase 4 Study to Evaluate the Safety and Immunogenicity of Monovalent Oral Polio Vaccine Type 2 in Healthy Children Aged 1 to 5 Years and in bOPV-IPV Vaccinated Healthy Infants	Completed	NCT02521974	Phase 4
50	Assessment of Poliovirus Type 2 Immunogenicity of One and Two Dose Schedule With IPV and fIPV	Recruiting	NCT03890497	Phase 4

Search NIH Clinical Center for Poliomyelitis

Cochrane evidence based reviews: poliomyelitis

Sources

Genetic Tests for Poliomyelitis

Sources

Anatomical Context for Poliomyelitis

Organs/tissues related to Poliomyelitis:

MalaCards : Spinal Cord, Skeletal Muscle, Bone Marrow, Kidney, Bone, Brain, Lung

Sources

Publications for Poliomyelitis

Articles related to Poliomyelitis:

(show top 50) (show all 22024)

#	Title	Authors	PMID	Year
1	Stable isotope labeling by amino acids in cell culture and differential plasma membrane proteome quantitation identify new substrates for the MARCH9 transmembrane E3 ligase. ⁵³ ⁶²	Hor S...Lehner PJ	19457934	2009
2	Novel BTK mutation presenting with vaccine-associated paralytic poliomyelitis. ⁵³ ⁶²	Mamishi S...Parvaneh N	18317803	2008
3	Evidence for emergence of diverse polioviruses from C-cluster coxsackie A viruses and implications for global poliovirus eradication. ⁵³ ⁶²	Jiang P...Gorbalenya AE	17517601	2007
4	Feasibility study to develop a common in vitro D antigen assay for inactivated poliomyelitis vaccines. ⁵³ ⁶²	Morgeaux S...Daas A	16336935	2005
5	A poliomyelitis model through mucosal infection in transgenic mice bearing human poliovirus receptor, TgPVR21. ⁵³ ⁶²	Nagata N...Nomoto A	15033568	2004
6	Injection-site reactions to booster doses of acellular pertussis vaccine: rate, severity, and anticipated impact. ⁵³ ⁶²	Skowronski DM...Scheifele D	14654644	2003
7	Tissue-specific replicating capacity of a chimeric poliovirus that carries the internal ribosome entry site of hepatitis C virus in a new mouse model transgenic for the human poliovirus receptor. ⁵³ ⁶²	Yanagiya A...Nomoto A	12970433	2003
8	Establishment of European Pharmacopoeia BRP batch 2 for inactivated poliomyelitis vaccine for in vitro D antigen assay. ⁵³ ⁶²	Fuchs F...Milne C	14563307	2003
9	The neuropathology observed in wild-type mice inoculated with human poliovirus mirrors human paralytic poliomyelitis. ⁵³ ⁶²	Ford DJ...Jubelt B	12220986	2002
10	Recent insights into poliovirus pathogenesis. ⁵³ ⁶²	Ohka S...Nomoto A	11597452	2001
11	Identification of a nuclear respiratory factor-1 binding site within the core promoter of the human polio virus receptor/CD155 gene. ⁵³ ⁶²	Solecki D...Wimmer E	10777530	2000
12	Expression of the poliovirus receptor in intestinal epithelial cells is not sufficient to permit poliovirus replication in the mouse gut. ⁵³ ⁶²	Zhang S...Racaniello VR	9188553	1997
13	Inactivated poliovirus vaccine protects transgenic poliovirus receptor mice against type 3 poliovirus challenge. ⁵³ ⁶²	Taffs RE...Asher DM	9203668	1997
14	Identification of two determinants that attenuate vaccine-related type 2 poliovirus. ⁵³ ⁶²	Ren RB...Racaniello VR	1847458	1991
15	Prior poliomyelitis-reduced capillary supply and metabolic enzyme content in hypertrophic slow-twitch (type I) muscle fibres. ⁵³ ⁶²	Borg K...Henriksson J	2030351	1991
16	Transgenic mice expressing a human poliovirus receptor: a new model for poliomyelitis. ⁵³ ⁶²	Ren RB...Racaniello VR	2170026	1990
17	The resurgence of polio: The effect of the Covid-19 pandemic on polio eradication. ⁶²	Niaz F...Tariq R	36471883	2023
18	Rare recurrences of poliomyelitis in non-endemic countries after eradication: a call for global action. ⁶²	Mercader-Barcelo J...Ebenso B	36084661	2022
19	Surveillance on the adverse events following immunization with the pentavalent vaccine in Zhejiang, China. ⁶²	Pan X...Hu Y	35108152	2022
20	Gaps in knowledge about the vaccine coverage of immunocompromised children: a scoping review. ⁶²	MacDonald SE...Burton C	34270376	2022
21	The progress of postapproval clinical studies on Sabin IPV. ⁶²	Shi L...Sun M	34213408	2022
22	Safety evaluation on concomitant immunization with inactivated poliomyelitis vaccine produced from Sabin strains and other vaccines (from 2015 to 2020). ⁶²	Deng Y...Yang J	35258415	2022
23	Review of scientific evidence to support recommendations of the full-dose DTaP-IPV vaccination in pre-school age children in Italy. ⁶²	Bechini A...Boccalini S	36178008	2022
24	Lot-to-lot consistency of a hexavalent DTwP-IPV-HB-PRP∼T vaccine and non-inferiority to separate DTwP-HB-PRP∼T and IPV antigen-matching vaccines at 6-8, 10-12, and 14-16 weeks of age co-administered with oral rotavirus vaccine in healthy infants in India: A multi-center, randomized, controlled study. ⁶²	Mangarule S...Noriega F	36164460	2022
25	Reminders of existing vaccine mandates increase support for a COVID-19 vaccine mandate: Evidence from a survey experiment. ⁶²	Viskupic F...Badahdah A	35985888	2022
26	Is it just a cure? Re-evaluating the effects of prenatal exposure to the Great Chinese Famine on the risk of infectious diseases in adulthood. ⁶²	He P...Zheng X	36335705	2022
27	The impact of different IPV-OPV sequential immunization programs on hepatitis A and hepatitis B vaccine efficacy. ⁶²	Chen S...Yang J	35044877	2022
28	May I Have This Dance: A Case-Series on the Acute Cardiometabolic Demand of Wheelchair Dancing in Recreational Dancers with Spinal Cord Injury. ⁶²	Shackleton C...Krassioukov AV	36455111	2022
29	Highlights From Infectious Disease Week 2022-COVID-19, HIV, Monkeypox, and Polio. ⁶²	Suran M	36350667	2022
30	Sustainable financing for Immunization Agenda 2030. ⁶²	Saxenian H...Ranson MK	36464542	2022
31	New Challenges in the Global Eradication of Polio. ⁶²		36384782	2022
32	Assessment of serological responses following vaccination campaigns with type 2 novel oral polio vaccine: a population-based study in Tajikistan in 2021. ⁶²	Mirzoev A...Mach O	36400086	2022
33	Effectiveness of a new vaccine for outbreak response and the increasingly complicated polio endgame. ⁶²	Thompson KM	36400075	2022
34	Development of an animal component free production process for Sabin inactivated polio vaccine. ⁶²	Suarez-Zuluaga DA...Thomassen YE	36217423	2022
35	Strengthened surveillance revealed a rapid disappearance of the poliovirus serotype 2 vaccine strain in Madagascar after its removal from the oral polio vaccine. ⁶²	Razafindratsimandresy R...Bessaud M	35977919	2022
36	Effects of maternal antibodies in infants on the immunogenicity and safety of inactivated polio vaccine in infants. ⁶²	Gao S...Zhu F	35394898	2022
37	Polio. ⁶²	Pucchio AMR...Salvadori MI	36379554	2022
38	A Polio Epidemic Is Averted. ⁶²	Todd B	36261905	2022
39	Polio has recently been detected in places like London, New York, Ukraine and Israel-but what does it really mean to the global eradication effort? ⁶²	O'Leary A	36342124	2022
40	Polio outbreak: An ongoing but ignored public health emergency of international concern - Correspondence. ⁶²	Farahat RA...Memish ZA	36332784	2022
41	Polio outbreak: A longest and ongoing global public health emergency. ⁶²	Sah R...Mehta R	36055552	2022
42	Global polio eradication; can we replicate the smallpox success story? ⁶²	Javed H...Raza MA	36426668	2022
43	Polio in New York: will it just go away? ⁶²	Fortner R	36319024	2022
44	Immunity to poliovirus in Afghanistan: A household sampling method for serological assessment based on geographical information systems. ⁶²	Mendes A...Farag NH	36468597	2022
45	Lessons from Vaccine-Related Poliovirus in Israel, UK and USA. ⁶²	John TJ...Dharmapalan D	36423064	2022
46	Outbreak response strategies with type 2-containing oral poliovirus vaccines. ⁶²	Kalkowska DA...Thompson KM	36402659	2022
47	What has been learned about COVID-19 vaccine hesitancy in Pakistan: Insights from a narrative review. ⁶²	Tharwani ZH...Essar MY	36425896	2022
48	Childhood immunization and age-appropriate vaccinations in Indonesia. ⁶²	Chu H...Rammohan A	36333713	2022
49	Recent Advances in Delivery Systems for Genetic and Other Novel Vaccines. ⁶²	Huang S...Zhang Z	34914144	2022
50	Risk factors associated with non-vaccination in Gambian children: a population-based cohort study. ⁶²	Young B...Mackenzie G	35696088	2022

Sources

Genes for Poliomyelitis

Genes related to Poliomyelitis (0 elite genes):

(show all 28)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	PVR	PVR Cell Adhesion Molecule	Protein Coding	26.71	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	9188553 10777530 11597452 (more) 9203668 19457934 2170026 1847458 12970433 12220986 15033568 17517601
2	IL10	Interleukin 10	Protein Coding	12.78	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
3	IFNG	Interferon Gamma	Protein Coding	12.37	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
4	ICAM1	Intercellular Adhesion Molecule 1	Protein Coding	12.2	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
5	FCGR3A	Fc Gamma Receptor IIIa	Protein Coding	11.91	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
6	FCGR3B	Fc Gamma Receptor IIIb	Protein Coding	11.64	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
7	FCGR2A	Fc Gamma Receptor IIa	Protein Coding	11.25	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
8	BTK	Bruton Tyrosine Kinase	Protein Coding	7.36	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	18317803
9	DLG1	Discs Large MAGUK Scaffold Protein 1	Protein Coding	7.29	GeneCards inferred via : Publications (show sections)
10	RASA3	RAS P21 Protein Activator 3	Protein Coding	6.59	DISEASES inferred ¹⁴
11	CD4	CD4 Molecule	Protein Coding	6.26	DISEASES inferred ¹⁴
12	CD8A	CD8a Molecule	Protein Coding	6.18	DISEASES inferred ¹⁴
13	PI4KB	Phosphatidylinositol 4-Kinase Beta	Protein Coding	6.02	DISEASES inferred ¹⁴
14	ACBD3	Acyl-CoA Binding Domain Containing 3	Protein Coding	5.88	DISEASES inferred ¹⁴
15	EIF4G1	Eukaryotic Translation Initiation Factor 4 Gamma 1	Protein Coding	5.77	DISEASES inferred ¹⁴
16	RIGI	RNA Sensor RIG-I	Protein Coding	5.76	DISEASES inferred ¹⁴
17	HLA-B	Major Histocompatibility Complex, Class I, B	Protein Coding	5.67	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	14654644
18	IFNB1	Interferon Beta 1	Protein Coding	5.67	DISEASES inferred ¹⁴
19	TNF	Tumor Necrosis Factor	Protein Coding	5.63	DISEASES inferred ¹⁴
20	TLR3	Toll Like Receptor 3	Protein Coding	5.62	DISEASES inferred ¹⁴
21	IFNA1	Interferon Alpha 1	Protein Coding	5.6	DISEASES inferred ¹⁴
22	IFIH1	Interferon Induced With Helicase C Domain 1	Protein Coding	5.6	DISEASES inferred ¹⁴
23	ACE2	Angiotensin Converting Enzyme 2	Protein Coding	5.58	DISEASES inferred ¹⁴
24	IL6	Interleukin 6	Protein Coding	5.57	DISEASES inferred ¹⁴
25	IL2	Interleukin 2	Protein Coding	5.47	DISEASES inferred ¹⁴
26	MAVS	Mitochondrial Antiviral Signaling Protein	Protein Coding	5.45	DISEASES inferred ¹⁴
27	ALB	Albumin	Protein Coding	5.38	DISEASES inferred ¹⁴
28	IRF3	Interferon Regulatory Factor 3	Protein Coding	5.32	DISEASES inferred ¹⁴

Sources

Variations for Poliomyelitis

Sources

Expression for Poliomyelitis

Search GEO for disease gene expression data for Poliomyelitis.

Sources

Pathways for Poliomyelitis

Pathways related to Poliomyelitis according to GeneCards Suite gene sharing:

(show all 44)

#	Super pathways	Score	Top Affiliating Genes
1	Disease ⁶⁶ Show member pathways Infectious disease ⁶⁶	13.77	TLR3 RIGI IL10 IFNB1 HLA-B FCGR3A
2	TGF-Beta Pathway ⁶⁴ Show member pathways JAK-STAT Pathway ⁶⁴ JNK Pathway ⁶⁴ MAPK Family Pathway ⁶⁴ Regulation of eIF4 and p70S6K ⁶⁴ SOCS Pathway ⁶⁴	13.5	TNF IL10 IFNG IFNB1 ICAM1 EIF4G1
3	Cytokine Signaling in Immune system ⁶⁶ Show member pathways Signaling by Interleukins ⁶⁶	13.27	TNF RIGI IL10 IFNG IFNB1 ICAM1
4	Innate Immune System ⁶⁶ Show member pathways Immune System ⁶⁶ Neutrophil degranulation ⁶⁶	13.08	TNF TLR3 RIGI PVR IL10 IFNG
5	Toll-like receptor signaling pathway ⁷⁴ Show member pathways Hepatitis B infection ⁷⁴ Measles virus infection ⁷⁴ Regulation of toll-like receptor signaling pathway ⁷⁴	12.81	BTK IFNB1 RIGI TLR3 TNF
6	Overview of interferons-mediated signaling pathway ⁷⁴ Show member pathways all-trans-Retinoic Acid Mediated Apoptosis ⁶⁴ Cytokine Network ⁶⁴ Immune response IFN alpha/beta signaling pathway ²² Interferon alpha/beta signaling ⁶⁶ Jak/STAT Signaling Pathway ⁶⁵ Regulation of IFNA/IFNB signaling ⁶⁶ Type III interferon signaling ⁷⁴	12.6	TNF IL10 IFNG IFNB1 HLA-B
7	Interferon gamma signaling ⁶⁶ Show member pathways Interferon Signaling ⁶⁶ Regulation of IFNG signaling ⁶⁶	12.52	RIGI IFNG IFNB1 ICAM1 HLA-B EIF4G1
8	NF-kappaB Signaling ³	12.44	TNF TLR3 RIGI PVR IL10 IFNG
9	DDX58/IFIH1-mediated induction of interferon-alpha/beta ⁶⁶ Show member pathways Immune response TLR3 and TLR4 induce TICAM1-specific signaling pathway ²² Negative regulators of DDX58/IFIH1 signaling ⁶⁶ NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10 ⁶⁶ Novel intracellular components of RIG-I-like receptor pathway ⁷⁴ SARS-CoV-2 B.1.1.7 variant antagonises innate immune activation ⁷⁴ TRAF3-dependent IRF activation pathway ⁶⁶ TRAF6 mediated IRF7 activation ⁶⁶	12.41	TLR3 RIGI IFNG IFNB1
10	Immune response CD16 signaling in NK cells ²² Show member pathways Immune response Role of DAP12 receptors in NK cells ²²	12.16	TNF IFNG HLA-B FCGR3A
11	Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell ⁶⁶	12.05	CD8A FCGR3A HLA-B ICAM1 PVR
12	Spinal cord injury ⁷⁴	11.95	TNF IFNG ICAM1 FCGR2A
13	Hematopoietic Stem Cells and Lineage-specific Markers ⁶⁵	11.91	TNF IL10 IFNG FCGR2A CD8A CD4
14	IL27-mediated signaling events ⁶¹ Show member pathways IL12 signaling pathway ⁶⁷ Th1 Differentiation ⁶⁵	11.88	TNF TLR3 IL10 IFNG CD4
15	Allograft rejection ⁷⁴	11.85	TNF IL10 IFNG HLA-B
16	Host-pathogen interaction of human coronaviruses - interferon induction ⁷⁴ Show member pathways Peginterferon alpha-2a/Peginterferon alpha-2b Pathway (Hepatocyte), Pharmacodynamics ⁶⁰ SARS coronavirus and innate immunity ⁷⁴ Type I interferon induction and signaling during SARS-CoV-2 infection ⁷⁴	11.84	TLR3 RIGI IFNB1
17	Th17 Differentiation ⁶⁵ Show member pathways IL-21 Signaling and its Primary Biological Effects in Different Immune Cell Types ⁶⁵	11.82	TLR3 IFNG CD4
18	Activation of NF-KappaB by PKR ⁶⁴ Show member pathways Canonical NF-kB pathway ⁷⁴ Cellular Transformation by HTLV1 ⁶⁴ Inhibition of PKR ⁶⁶ STING pathway in Kawasaki-like disease and COVID-19 ⁷⁴	11.77	FCGR2A IFNB1 IFNG TNF
19	Network map of SARS-CoV-2 signaling pathway ⁷⁴ Show member pathways Pathogenesis of SARS-CoV-2 mediated by nsp9-nsp10 complex ⁷⁴	11.74	IFNB1 CD8A CD4
20	Glucocorticoid receptor regulatory network ⁶¹	11.73	IFNG ICAM1 FCGR2A
21	Innate Lymphoid Cells Differentiation ⁶⁵	11.73	TNF IL10 IFNG CD8A CD4
22	Burn wound healing ⁷⁴	11.72	TNF IFNB1 ICAM1
23	Extrafollicular B cell activation by SARS-CoV-2 ⁷⁴	11.69	TNF IL10 IFNG
24	Acute viral myocarditis ⁷⁴	11.68	CD4 EIF4G1 IFNG IL10 TLR3
25	T-cell activation SARS-CoV-2 ⁷⁴ Show member pathways T-cell antigen receptor (TCR) pathway during Staphylococcus aureus infection ⁷⁴	11.68	TNF IL10 IFNG IFNB1 DLG1 CD8A
26	Photodynamic therapy-induced NF-kB survival signaling ⁷⁴ Show member pathways Immune response MIF-mediated glucocorticoid regulation ²²	11.63	ICAM1 IFNG TNF
27	miRNAs involvement in the immune response in sepsis ⁷⁴	11.62	TNF IL10 ICAM1
28	Inflammatory bowel disease signaling ⁷⁴ Show member pathways Ulcerative colitis signaling ⁷⁴	11.59	TNF IL10 IFNG
29	NF-kB (NFkB) Pathway ⁶⁷	11.56	TNF CD4 BTK
30	SARS-CoV-2 innate immunity evasion and cell-specific immune response ⁷⁴	11.56	TNF RIGI IL10 IFNB1
31	Netrin-UNC5B signaling pathway ⁷⁴	11.53	TNF IL10 ICAM1
32	THC Differentiation Pathway ⁶⁴	11.5	TNF IL10 IFNG CD4
33	Dendritic Cells Developmental Lineage Pathway ⁶⁵	11.5	CD4 CD8A IFNB1 IFNG IL10 TNF
34	Interleukin-10 signaling ⁶⁶	11.48	TNF IL10 ICAM1
35	Th2 Differentiation ⁶⁵	11.46	CD4 IFNG IL10
36	Fibrin complement receptor 3 signaling pathway ⁷⁴	11.43	TNF TLR3 IFNB1
37	Type II interferon signaling ⁷⁴	11.38	IFNG IFNB1 ICAM1 HLA-B
38	Heparin-induced Thrombocytopenia Pathway, Adverse Drug Reaction ⁶⁰	11.36	IL10 FCGR3A FCGR2A CD4
39	Kynurenine pathway and links to cell senescence ⁷⁴ Show member pathways Tryptophan catabolism ⁶⁶	11.34	TNF IFNG IFNB1
40	IL-15 Signaling and its Primary Biological Effects in Different Immune Cell Types ⁶⁵ Show member pathways IL-2 Signaling and its Primary Biological Effects in Different Immune Cell Types ⁶⁵	11.34	TNF IL10 IFNG
41	Immune infiltration in pancreatic cancer ⁷⁴	11.19	TNF IL10 IFNG
42	Interactions of natural killer cells in pancreatic cancer ⁷⁴	11.19	TNF PVR IFNG FCGR3A
43	Cytokines and inflammatory response ⁷⁴	11.12	TNF IL10 IFNG IFNB1 CD4
44	mRNA vaccine activation of dendritic cell and induction of IFN-1 ⁷⁴	10.68	TLR3 RIGI

Sources

GO Terms for Poliomyelitis

Cellular components related to Poliomyelitis according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	plasma membrane	GO:0005886	9.74	TNF TLR3 ICAM1 HLA-B FCGR3B FCGR3A
2	plasma membrane	GO:0005887	9.74	TNF TLR3 ICAM1 HLA-B FCGR3B FCGR3A
3	membrane raft	GO:0045121	9.65	TNF ICAM1 DLG1 CD4 BTK

Biological processes related to Poliomyelitis according to GeneCards Suite gene sharing:

(show all 24)

#	Name	GO ID	Score	Top Affiliating Genes
1	adaptive immune response	GO:0002250	10.36	IFNG IFNB1 HLA-B CD8A CD4 BTK
2	calcium-mediated signaling	GO:0019722	10.1	TNF FCGR3A CD4 BTK
3	positive regulation of phagocytosis	GO:0050766	10.09	TNF IFNG BTK
4	positive regulation of inflammatory response	GO:0050729	10.09	TNF TLR3 IFNG BTK
5	positive regulation of chemokine production	GO:0032722	10.08	TNF TLR3 IFNG
6	regulation of immune response	GO:0050776	10.08	FCGR3B FCGR3A FCGR2A
7	response to exogenous dsRNA	GO:0043330	10.04	IFNB1 RIGI TLR3
8	response to virus	GO:0009615	10.02	IFNB1 IFNG RIGI TLR3 TNF
9	positive regulation of tumor necrosis factor production	GO:0032760	10.02	TLR3 RIGI IFNG FCGR3A BTK
10	cell surface receptor signaling pathway	GO:0007166	10	IFNG IFNB1 FCGR3B FCGR3A FCGR2A CD8A
11	microglial cell activation	GO:0001774	9.99	TNF TLR3 IFNG
12	positive regulation of cytokine production	GO:0001819	9.98	TNF TLR3 IL10 IFNG
13	defense response	GO:0006952	9.97	TNF TLR3 IFNB1 HLA-B
14	positive regulation of interleukin-6 production	GO:0032755	9.96	BTK IFNG RIGI TLR3 TNF
15	detection of virus	GO:0009597	9.91	TLR3 RIGI
16	negative regulation of cytokine production involved in immune response	GO:0002719	9.89	IL10 TNF
17	cellular response to exogenous dsRNA	GO:0071360	9.88	TLR3 RIGI IFNB1
18	positive regulation of synoviocyte proliferation	GO:1901647	9.86	TNF BTK
19	positive regulation of calcidiol 1-monooxygenase activity	GO:0060559	9.84	TNF IFNG
20	positive regulation of nitrogen compound metabolic process	GO:0051173	9.83	TNF IFNG
21	chronic inflammatory response to antigenic stimulus	GO:0002439	9.78	IL10 TNF
22	positive regulation of vitamin D biosynthetic process	GO:0060557	9.76	IFNG TNF
23	immune system process	GO:0002376	9.61	BTK CD4 CD8A FCGR2A FCGR3A HLA-B
24	immune response	GO:0006955	9.47	TNF TLR3 IL10 IFNG HLA-B FCGR3B